Michael Lankiewicz
Hematology · Newark, DENPI 1982717930
Payments from drug & device makers
Across 112 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$380
- Johnson & Johnson$336
- AstraZeneca$129
- Gilead$114
- Seagen Inc.$108
- Amgen$105
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,18496%
- Education$1014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $380 |
| Johnson & Johnson(2 entities) | 17 | $336 |
| AstraZeneca(2 entities) | 6 | $129 |
| Gilead(2 entities) | 6 | $114 |
| Seagen Inc. | 3 | $108 |
| Amgen | 6 | $105 |
| AbbVie | 7 | $98 |
| Verastem, Inc. | 4 | $82 |
| Jazz Pharmaceuticals Inc. | 4 | $80 |
| Bristol Myers Squibb | 4 | $74 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Merck | 3 | $61 |
| Pfizer | 4 | $61 |
| Novartis | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| Rigel Pharmaceuticals, Inc. | 3 | $45 |
| Partner Therapeutics, Inc. | 2 | $38 |
| Haemonetics Corporation | 1 | $37 |
| Astellas Pharma US Inc | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $32 |
| Agios Pharmaceuticals, Inc. | 2 | $29 |
| EUSA Pharma (US) LLC | 2 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Incyte Corporation | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Spectrum Pharmaceuticals Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$138
How this compares
Too few hematology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $17,788 |
| Acyclovir | 30 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $336 | $17,78811 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $59 | $79230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other hematology in Newark
- Scott HallNewark$49K
- Paramveer SinghNewark$2K
- Robert SleaseNewark$480
- Philip BlattNewark$31
- Vinay Edlukudige KeshavaDover$179
- Sheeba Habeeb Ba AqeelDover$114
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.